– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback